Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature

Abstract Objectives To develop and validate an 18F-FDG PET/CT-based clinical-radiological-radiomics nomogram and evaluate its value in the diagnosis of MYCN amplification (MNA) in paediatric neuroblastoma (NB) patients. Methods A total of 104 patients with NB were retrospectively included. We constr...

Full description

Bibliographic Details
Main Authors: Luo-Dan Qian, Shu-Xin Zhang, Si-Qi Li, Li-Juan Feng, Zi-Ang Zhou, Jun Liu, Ming-Yu Zhang, Ji-Gang Yang
Format: Article
Language:English
Published: SpringerOpen 2023-11-01
Series:Insights into Imaging
Subjects:
Online Access:https://doi.org/10.1186/s13244-023-01493-8
_version_ 1797452387726655488
author Luo-Dan Qian
Shu-Xin Zhang
Si-Qi Li
Li-Juan Feng
Zi-Ang Zhou
Jun Liu
Ming-Yu Zhang
Ji-Gang Yang
author_facet Luo-Dan Qian
Shu-Xin Zhang
Si-Qi Li
Li-Juan Feng
Zi-Ang Zhou
Jun Liu
Ming-Yu Zhang
Ji-Gang Yang
author_sort Luo-Dan Qian
collection DOAJ
description Abstract Objectives To develop and validate an 18F-FDG PET/CT-based clinical-radiological-radiomics nomogram and evaluate its value in the diagnosis of MYCN amplification (MNA) in paediatric neuroblastoma (NB) patients. Methods A total of 104 patients with NB were retrospectively included. We constructed a nomogram to predict MNA based on radiomics signatures, clinical and radiological features. The multivariable logistic regression and the least absolute shrinkage and selection operator (LASSO) were used for feature selection. Radiomics models are constructed using decision trees (DT), logistic regression (LR) and support vector machine (SVM) classifiers. A clinical-radiological (C-R) model was developed using clinical and radiological features. A clinical-radiological-radiomics (C-R-R) model was developed using the C-R model of the best radiomics model. The prediction performance was verified by receiver operating characteristic (ROC) curve analysis, calibration curve analysis and decision curve analysis (DCA) in the training and validation cohorts. Results The present study showed that four radiomics signatures were significantly correlated with MNA. The SVM classifier was the best model of radiomics signature. The C-R-R model has the best discriminant ability to predict MNA, with AUCs of 0.860 (95% CI, 0.757–0.963) and 0.824 (95% CI, 0.657–0.992) in the training and validation cohorts, respectively. The calibration curve indicated that the C-R-R model has the goodness of fit and DCA confirms its clinical utility. Conclusion Our research provides a non-invasive C-R-R model, which combines the radiomics signatures and clinical and radiological features based on 18F-FDGPET/CT images, shows excellent diagnostic performance in predicting MNA, and can provide useful biological information with stratified therapy. Critical relevance statement Radiomic signatures of 18F-FDG-based PET/CT can predict MYCN amplification in neuroblastoma. Key points • Radiomic signatures of 18F-FDG-based PET/CT can predict MYCN amplification in neuroblastoma. • SF, LDH, necrosis and TLG are the independent risk factors of MYCN amplification. • Clinical-radiological-radiomics model improved the predictive performance of MYCN amplification. Graphical Abstract
first_indexed 2024-03-09T15:07:41Z
format Article
id doaj.art-3808518c33024ade894d1d68837ce8b6
institution Directory Open Access Journal
issn 1869-4101
language English
last_indexed 2024-03-09T15:07:41Z
publishDate 2023-11-01
publisher SpringerOpen
record_format Article
series Insights into Imaging
spelling doaj.art-3808518c33024ade894d1d68837ce8b62023-11-26T13:33:11ZengSpringerOpenInsights into Imaging1869-41012023-11-0114111210.1186/s13244-023-01493-8Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signatureLuo-Dan Qian0Shu-Xin Zhang1Si-Qi Li2Li-Juan Feng3Zi-Ang Zhou4Jun Liu5Ming-Yu Zhang6Ji-Gang Yang7Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical UniversityAbstract Objectives To develop and validate an 18F-FDG PET/CT-based clinical-radiological-radiomics nomogram and evaluate its value in the diagnosis of MYCN amplification (MNA) in paediatric neuroblastoma (NB) patients. Methods A total of 104 patients with NB were retrospectively included. We constructed a nomogram to predict MNA based on radiomics signatures, clinical and radiological features. The multivariable logistic regression and the least absolute shrinkage and selection operator (LASSO) were used for feature selection. Radiomics models are constructed using decision trees (DT), logistic regression (LR) and support vector machine (SVM) classifiers. A clinical-radiological (C-R) model was developed using clinical and radiological features. A clinical-radiological-radiomics (C-R-R) model was developed using the C-R model of the best radiomics model. The prediction performance was verified by receiver operating characteristic (ROC) curve analysis, calibration curve analysis and decision curve analysis (DCA) in the training and validation cohorts. Results The present study showed that four radiomics signatures were significantly correlated with MNA. The SVM classifier was the best model of radiomics signature. The C-R-R model has the best discriminant ability to predict MNA, with AUCs of 0.860 (95% CI, 0.757–0.963) and 0.824 (95% CI, 0.657–0.992) in the training and validation cohorts, respectively. The calibration curve indicated that the C-R-R model has the goodness of fit and DCA confirms its clinical utility. Conclusion Our research provides a non-invasive C-R-R model, which combines the radiomics signatures and clinical and radiological features based on 18F-FDGPET/CT images, shows excellent diagnostic performance in predicting MNA, and can provide useful biological information with stratified therapy. Critical relevance statement Radiomic signatures of 18F-FDG-based PET/CT can predict MYCN amplification in neuroblastoma. Key points • Radiomic signatures of 18F-FDG-based PET/CT can predict MYCN amplification in neuroblastoma. • SF, LDH, necrosis and TLG are the independent risk factors of MYCN amplification. • Clinical-radiological-radiomics model improved the predictive performance of MYCN amplification. Graphical Abstracthttps://doi.org/10.1186/s13244-023-01493-8Neuroblastoma18F-FDG PET/CTRadiogenomicsMYCN
spellingShingle Luo-Dan Qian
Shu-Xin Zhang
Si-Qi Li
Li-Juan Feng
Zi-Ang Zhou
Jun Liu
Ming-Yu Zhang
Ji-Gang Yang
Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature
Insights into Imaging
Neuroblastoma
18F-FDG PET/CT
Radiogenomics
MYCN
title Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature
title_full Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature
title_fullStr Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature
title_full_unstemmed Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature
title_short Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature
title_sort predicting mycn amplification in paediatric neuroblastoma development and validation of a 18f fdg pet ct based radiomics signature
topic Neuroblastoma
18F-FDG PET/CT
Radiogenomics
MYCN
url https://doi.org/10.1186/s13244-023-01493-8
work_keys_str_mv AT luodanqian predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature
AT shuxinzhang predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature
AT siqili predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature
AT lijuanfeng predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature
AT ziangzhou predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature
AT junliu predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature
AT mingyuzhang predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature
AT jigangyang predictingmycnamplificationinpaediatricneuroblastomadevelopmentandvalidationofa18ffdgpetctbasedradiomicssignature